OncoMatch/Clinical Trials/NCT05357846
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Is NCT05357846 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Sintilimab and Paclitaxel for squamous cell esophageal carcinoma.
Treatment: Sintilimab · Paclitaxel · Cisplatin — The primary objective is to compare PD-1 inhibitor combined with preoperative chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery, in terms of the overall survival time (OS) in patients with Stage T1-4aN1-3M0 or T3-4aN0M0 squamous cell esophageal carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage T1-4AN1-3M0, T3-4AN0M0
Stage T1-4aN1-3M0 or T3-4aN0M0, which is potentially resectable
Performance status
WHO 0–1
Demographics
Prior therapy
Cannot have received: anticancer therapy
Patients must not have received any prior anticancer therapy
Lab requirements
Blood counts
absolute white blood cells count ≥4.0×109/l, neutrophil ≥1.5×109/l, platelets ≥100.0×109/l, hemoglobin ≥90g/l
Kidney function
normal functions of kidney
Liver function
normal functions of liver
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05357846 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage T1-4AN1-3M0 or T3-4AN0M0 is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages